These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27812140)

  • 21. Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India.
    Sachdeva KS; Raizada N; Sreenivas A; Van't Hoog AH; van den Hof S; Dewan PK; Thakur R; Gupta RS; Kulsange S; Vadera B; Babre A; Gray C; Parmar M; Ghedia M; Ramachandran R; Alavadi U; Arinaminpathy N; Denkinger C; Boehme C; Paramasivan CN
    PLoS One; 2015; 10(5):e0126065. PubMed ID: 25996389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children.
    Kay AW; González Fernández L; Takwoingi Y; Eisenhut M; Detjen AK; Steingart KR; Mandalakas AM
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013359. PubMed ID: 32853411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.
    Chatla C; Jaju J; Achanta S; Samyuktha R; Chakramahanti S; Purad C; Chepuri R; Nair SA; Parmar M
    Indian J Tuberc; 2018 Jul; 65(3):218-224. PubMed ID: 29933863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of an Xpert-based diagnostic algorithm for the rapid detection of drug-resistant tuberculosis among high-risk populations in a low-incidence setting.
    Chiang TY; Fan SY; Jou R
    PLoS One; 2018; 13(7):e0200755. PubMed ID: 30011319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Introducing Xpert MTB/RIF on Diagnosis and Treatment of Drug-Resistant Tuberculosis Patients in Indonesia: A Pre-Post Intervention Study.
    van Kampen SC; Susanto NH; Simon S; Astiti SD; Chandra R; Burhan E; Farid MN; Chittenden K; Mustikawati DE; Alisjahbana B
    PLoS One; 2015; 10(6):e0123536. PubMed ID: 26075722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand.
    Kawkitinarong K; Suwanpimolkul G; Kateruttanakul P; Manosuthi W; Ubolyam S; Sophonphan J; Avihingsanon A; Ruxrungtham K
    Clin Infect Dis; 2017 May; 64(suppl_2):S171-S178. PubMed ID: 28475796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Xpert
    Kohli M; Schiller I; Dendukuri N; Dheda K; Denkinger CM; Schumacher SG; Steingart KR
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012768. PubMed ID: 30148542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study.
    Namugenyi J; Musaazi J; Katamba A; Kalyango J; Sendaula E; Kambugu A; Fehr J; Castelnouvo B; Manabe YC; Ssengooba W; Sekaggya-Wiltshire C
    BMC Infect Dis; 2021 Jun; 21(1):513. PubMed ID: 34074248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.
    Iem V; Dean A; Zignol M; Vongvichit P; Inthavong D; Siphanthong S; Sorsavanh T; Kim SJ; Shin S; Sébert J; Chittamany P
    Trop Med Int Health; 2019 Apr; 24(4):421-431. PubMed ID: 30663180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.
    Pereira GR; Barbosa MS; Dias NJD; Almeida CPB; Silva DR
    PLoS One; 2018; 13(3):e0193988. PubMed ID: 29518135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing.
    Peter J; Theron G; Chanda D; Clowes P; Rachow A; Lesosky M; Hoelscher M; Mwaba P; Pym A; Dheda K;
    BMC Infect Dis; 2015 Jul; 15():262. PubMed ID: 26156025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts.
    Kawasaki M; Echiverri C; Raymond L; Cadena E; Reside E; Gler MT; Oda T; Ito R; Higashiyama R; Katsuragi K; Liu Y
    PLoS Med; 2019 Apr; 16(4):e1002780. PubMed ID: 30978194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.
    Cox HS; Mbhele S; Mohess N; Whitelaw A; Muller O; Zemanay W; Little F; Azevedo V; Simpson J; Boehme CC; Nicol MP
    PLoS Med; 2014 Nov; 11(11):e1001760. PubMed ID: 25423041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the Xpert® MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia.
    Mavenyengwa RT; Shaduka E; Maposa I
    Infect Dis Poverty; 2017 Jan; 6(1):13. PubMed ID: 28086955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru.
    Villegas L; Otero L; Sterling TR; Huaman MA; Van der Stuyft P; Gotuzzo E; Seas C
    PLoS One; 2016; 11(4):e0152933. PubMed ID: 27045684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa.
    Rabna P; Ramos J; Ponce G; Sanca L; Mané M; Armada A; Machado D; Vieira F; Gomes VF; Martins E; Colombatti R; Riccardi F; Perdigão J; Sotero J; Portugal I; Couto I; Atouguia J; Rodrigues A; Viveiros M
    PLoS One; 2015; 10(5):e0127536. PubMed ID: 26017968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial.
    Calligaro GL; Theron G; Khalfey H; Peter J; Meldau R; Matinyenya B; Davids M; Smith L; Pooran A; Lesosky M; Esmail A; Miller MG; Piercy J; Michell L; Dawson R; Raine RI; Joubert I; Dheda K
    Lancet Respir Med; 2015 Aug; 3(8):621-30. PubMed ID: 26208996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.